|
294 Companies |
|
490 Products |
|
490 Products |
|
198 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...145146147148149150151152153154155156157» |
- Zostavax (zoster vaccine live) / Merck (MSD)
New P1 trial: Zostavax in Systemic Lupus Erythematosus (clinicaltrials.gov) - Nov 16, 2011
P1, N=20, Completed, Sponsor: Oklahoma Medical Research Foundation
- ||||| Enrollment change: Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Nov 15, 2011
P3, N=920, Completed, Sponsor: Novartis
N=1250 --> 920
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P3 trial, Combination therapy: Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Nov 15, 2011
P3, N=200, Recruiting, Sponsor: Ming Hou
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed: Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy (clinicaltrials.gov) - Nov 15, 2011
P=N/A, N=20, Active, not recruiting, Sponsor: University of California, San Francisco
N=1250 --> 920 Recruiting --> Active, not recruiting
- ||||||| Trial completion: Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Nov 15, 2011
P3, N=920, Completed, Sponsor: Novartis
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change: Intervention Groups for Adolescents With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Nov 15, 2011
P=N/A, N=30, Completed, Sponsor: Children's Hospital and Health System Foundation, Wisconsin
Active, not recruiting --> Completed N=40 --> 30
- Trial completion: Intervention Groups for Adolescents With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Nov 15, 2011
P=N/A, N=30, Completed, Sponsor: Children's Hospital and Health System Foundation, Wisconsin
N=40 --> 30 Recruiting --> Completed
- | Jyseleca (filgotinib) / Galapagos, Gilead
Trial completion: Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients (clinicaltrials.gov) - Nov 14, 2011
P2, N=36, Completed, Sponsor: Galapagos NV
Recruiting --> Completed Recruiting --> Completed
- ||||||| Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang
Trial completion: PRESENT: PReventive Efficacy and Safety of rEbamipide on Nsaid Induced Mucosal Toxicity (clinicaltrials.gov) - Nov 14, 2011
P3, N=396, Completed, Sponsor: Korea Otsuka Pharmaceutical Co.,Ltd.
Recruiting --> Completed Recruiting --> Completed
- Enrollment change: CLASS-01: Closed-loop Control of Glucose Levels in the Context of Exercise in Adults With Type-1 Diabetes (clinicaltrials.gov) - Nov 14, 2011
P1/2, N=15, Completed, Sponsor: Institut de Recherches Cliniques de Montreal
Recruiting --> Completed N=10 --> 15
- ||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Monotherapy: A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs) (clinicaltrials.gov) - Nov 14, 2011
P3, N=886, Completed, Sponsor: Hoffmann-La Roche
N=10 --> 15 Recruiting --> Completed
- | firategrast (SB683699) / GSK
Trial completion: Healthy Volunteer Study Using 3 Different Formulations of Firategrast (clinicaltrials.gov) - Nov 13, 2011
P1, N=38, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Recruiting --> Completed
- | azithromycin / Generic mfg.
Biomarker, Trial completion: A Single and Repeat Dose PK/PD Study to Characterise Biomarker Response in Healthy Subjects Treated With Azithromycin (clinicaltrials.gov) - Nov 13, 2011
P=N/A, N=20, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Recruiting --> Completed
- |||| Doptelet (avatrombopag) / SOBI
Trial completion: Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Nov 13, 2011
P2, N=64, Completed, Sponsor: Eisai Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- Trial withdrawal: Ultrasound Assessment of Steroid Joint Injections in Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Nov 9, 2011
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: Ultrasound Assessment of Steroid Joint Injections in Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Nov 9, 2011
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Not yet recruiting --> Withdrawn N=75 --> 0
- ||| Betaseron (IFN-β-1b) / Bayer
Trial completion: Physical Disability in Patients Treated With Betaferon (clinicaltrials.gov) - Nov 9, 2011
P=N/A, N=83, Completed, Sponsor: Bayer
N=75 --> 0 Recruiting --> Completed
- | New P2 trial: WIRMS: Worms for Immune Regulation of Multiple Sclerosis (clinicaltrials.gov) - Nov 9, 2011
P2, N=72, Recruiting, Sponsor: University of Nottingham
- PD 360324 / Pfizer
New P1 trial: A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus (clinicaltrials.gov) - Nov 9, 2011
P1, N=28, Terminated, Sponsor: Pfizer
- Subcuvia (human normal immunoglobulin 16%) / Takeda
Trial completion: Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (clinicaltrials.gov) - Nov 8, 2011
P2, N=30, Completed, Sponsor: University of Aarhus
Recruiting --> Completed Active, not recruiting --> Completed
- trichuris suis ova (CNDO-201) / Fortress
Trial completion: TRIMS A: Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study (clinicaltrials.gov) - Nov 8, 2011
P2, N=10, Completed, Sponsor: Rigshospitalet, Denmark
Active, not recruiting --> Completed Not yet recruiting --> Completed
- New P2 trial: A Clinical Study of the Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM) (clinicaltrials.gov) - Nov 8, 2011
P2, N=16, Completed, Sponsor: University of Virginia
- Trial completion: Imaging Inflammation in Autoimmune Diabetes (clinicaltrials.gov) - Nov 8, 2011
P=N/A, N=30, Completed, Sponsor: Joslin Diabetes Center
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | Actemra IV (tocilizumab) / Roche, JW Pharma
New P2 trial: A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment (clinicaltrials.gov) - Nov 7, 2011
P2, N=48, Completed, Sponsor: Hoffmann-La Roche
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Nov 7, 2011
P1, N=40, Completed, Sponsor: Novo Nordisk
- | Trial completion: Managing Insulin Pumps for Exercise - Study 1 (clinicaltrials.gov) - Nov 6, 2011
P=N/A, N=16, Completed, Sponsor: Buckinghamshire Healthcare NHS Trust
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | thyroxine / Generic mfg.
New P4 trial: Selenium Supplementation in Pregnancy (clinicaltrials.gov) - Nov 3, 2011
P4, N=150, Recruiting, Sponsor: University of Roma La Sapienza
- | New P4 trial: Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes (clinicaltrials.gov) - Nov 3, 2011
P4, N=26, Completed, Sponsor: Novo Nordisk
- |||||||||| BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk
New P3 trial: Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes (clinicaltrials.gov) - Nov 3, 2011
P3, N=303, Completed, Sponsor: Novo Nordisk
- New P1 trial, IO biomarker: Nanotechnology for Detection of Multiple Sclerosis Compared to Autoimmune and Neurological Diseases by Exhaled Samples (clinicaltrials.gov) - Nov 2, 2011
P1, N=400, Recruiting, Sponsor: Carmel Medical Center
- Enrollment open: PreCARA: Preconceptional Counselling in Active Rheumatoid Arthritis (clinicaltrials.gov) - Nov 2, 2011
P=N/A, N=40, Recruiting, Sponsor: Erasmus Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Avonex (recombinant IFN-β-1a) / Biogen
Trial completion: Avonex China: Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) (clinicaltrials.gov) - Nov 2, 2011
P3, N=60, Completed, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: TYNERGY: Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS (clinicaltrials.gov) - Nov 2, 2011
P=N/A, N=60, Completed, Sponsor: Biogen Idec
Active, not recruiting --> Completed Recruiting --> Completed
- | GSK 2018682 / GSK
New P1 trial: A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. (clinicaltrials.gov) - Nov 2, 2011
P1, N=16, Completed, Sponsor: GlaxoSmithKline
- tacrolimus XR / Generic mfg.
Trial completion: Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis (clinicaltrials.gov) - Nov 1, 2011
P3, N=20, Completed, Sponsor: Sun Yat-sen University
Recruiting --> Completed Recruiting --> Completed
- | mavrilimumab (KPL-301) / Kiniksa
Trial completion: A Single Dose Study of the CAM-3001 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 1, 2011
P1, N=38, Completed, Sponsor: MedImmune Ltd
Recruiting --> Completed Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment open: Incritop: Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=199, Recruiting, Sponsor: Ming Hou
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Betaseron (IFN-?-1b) / Bayer
Enrollment change, Drug adherence, Adherence: POR-BetaPlus: Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=10, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting N=20 --> 10
- ||| Trial completion: A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in India (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=12000, Completed, Sponsor: Novo Nordisk
N=20 --> 10 Enrolling by invitation --> Completed
- Betaseron (IFN-?-1b) / Bayer
Trial completion, Drug adherence, Adherence: POR-BetaPlus: Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors (clinicaltrials.gov) - Oct 31, 2011
P=N/A, N=10, Completed, Sponsor: Bayer
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: Comparing the Metabolic Control of Once to Twice-daily Insulin Detemir Injections (clinicaltrials.gov) - Oct 31, 2011
P4, N=50, Completed, Sponsor: Rabin Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| New P2 trial: Web-based Support to Manage Arthritis Pain (clinicaltrials.gov) - Oct 30, 2011
P2, N=228, Completed, Sponsor: Inflexxion, Inc.
- ||||| Artlegia (olokizumab) - R / Pharm
New P2 trial: Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy (clinicaltrials.gov) - Oct 30, 2011
P2, N=119, Completed, Sponsor: UCB Japan Co. Ltd.
- | NovoLog (insulin aspart) / Novo Nordisk
New P1 trial: Bioequivalence of Two NovoLog (clinicaltrials.gov) - Oct 30, 2011
P1, N=24, Completed, Sponsor: Novo Nordisk
- |||| Humalog pen (insulin lispro) / Eli Lilly
Trial completion: A Study on the Effect of 2 Pen Devices on HbA1c (clinicaltrials.gov) - Oct 30, 2011
P4, N=263, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Effects of Training on Central Auditory Function in Multiple Sclerosis (clinicaltrials.gov) - Oct 27, 2011
P=N/A, N=158, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| Zinbryta (daclizumab) / Biogen, AbbVie
New P3 trial: An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 27, 2011
P3, N=135, Active, not recruiting, Sponsor: Biogen Idec
- Levemir (insulin detemir rDNA origin) / Novo Nordisk
New P3 trial: Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis (clinicaltrials.gov) - Oct 26, 2011
P3, N=19, Completed, Sponsor: University of Aarhus
- Trial completion: The Impact of Pancreatic Islet Cell Allotransplantation on Cognitive Function in Type 1 Diabetes Mellitus (clinicaltrials.gov) - Oct 25, 2011
P=N/A, N=36, Completed, Sponsor: Yale University
Recruiting --> Completed Recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Trial completion, PK/PD data: Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis (clinicaltrials.gov) - Oct 24, 2011
P3, N=25, Completed, Sponsor: Abbott
Recruiting --> Completed Active, not recruiting --> Completed